Windlas Biotech logo

Windlas Biotech financials: balance sheet, profit and loss, cash flow

NSE: WINDLASBSE: 543329Pharmaceuticals & BiotechnologySmall Cap

Windlas Biotech Limited · Face value ₹5 · Listed Aug 2021 · Issue price ₹460
Last close ₹877.40down ₹5.10 (0.58%)BSE ₹877.15

Share price at the NSE close on 27 Oct 2026. Previous close ₹882.50.

27 Oct: open ₹878.10, high ₹887.40, low ₹872.10

52-week range of traded prices to 27 Oct 2026
₹697.40Low, 16 Mar 2026₹1,181.90High, 7 Sep 2026
Market cap
₹1,811 Cr1,237th largest listed
P/E
27.26
P/B
3.12
Dividend yield
0.72%
ROE
12.2%
ROCE
12.2%
Debt to equity
0.05
Volume, NSE
70,47965.8% delivered

Windlas Biotech's financial statements for the 5 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them.

5 years at a glance

₹ crore, years to March.Windlas Biotech annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
466396.1Mar 22513430.4Mar 23631580.1Mar 247606127Mar 259046630Mar 26
Peak revenue ₹904 Cr, year to Mar 2026; lowest ₹466 Cr, year to Mar 2022

Operating and net margin, per cent

  • Operating margin
  • Net margin
12.4%7.3%11.4%11.7%12.4%12.4%11.6%8.3%8.3%9.2%8.0%7.3%Mar 22Mar 23Mar 24Mar 25Mar 26

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue904
  2. Materials and goods−557
  3. Employee costs−152
  4. Other expenses−90
  5. Operating profit105
  6. Depreciation−31
  7. Other income+18
  8. One-off items0.0
  9. Finance costs−4.8
  10. Profit before tax87
  11. Tax−20
  12. Net profit66

What the company owns

  • Plant, investments and other assets₹348 Cr
  • Current investments₹268 Cr
  • Receivables₹227 Cr
  • Inventory₹62 Cr
  • Cash and bank₹2 Cr

What pays for it: net worth and liabilities

  • Net worth₹581 Cr
  • Owed to suppliers₹238 Cr
  • Other liabilities₹58 Cr
  • Borrowings₹30 Cr

Profit and loss

Standalone, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Windlas Biotech quarterly results

₹ croreMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 21 MayJun 2026Twelve monthsFiled 10 Aug
Revenue from operations466513631760904942
413453553666799837
Materials and goods bought303325396472557580
Employee costs637087123152164
Other expenses475769719093
Operating profit before depreciation53607894105105
Operating margin11.4%11.7%12.4%12.4%11.6%11.1%
Materials, % of revenue65.0%63.4%62.8%62.1%61.6%61.6%
Employee costs, % of revenue13.6%13.7%13.9%16.2%16.8%17.4%
Other expenses, % of revenue10.0%11.1%11.0%9.3%10.0%9.8%
Depreciation and amortisation121213283131
Operating profit after depreciation414865667474
Other income71013181818
Finance costs111455
One-off items000000
Profit before tax465777798787
71419192020
Net profit394358616666
Other comprehensive income000−100
Total comprehensive income384258606766
Net margin8.3%8.3%9.2%8.0%7.3%7.1%

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 21 May
395403450506581
Share capital1110101011
Reserves384392440495570
6002730
94121171249321
25556
Total assets491529626760907
109175195235280
382354431525627
Net debt−173−132−204−212−240
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 21 May
96110968105
187112889120
−38644−9−4
Receivables−32−8−20−31−61
Inventories−17−1613−1920
Payables2324443661
Other working capital−12675−23
Tax paid−9−10−19−21−15
Capital spending1571385268
Free cash flow−6−10711637
−154−14−92−74−92
130−44−151−13
Dividends paid0881112
Shares bought back00000
Shares issued16527400
Net change in cash−1532−50
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Standalone, ₹ per share, years to March.Windlas Biotech dividend history

₹ per shareMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 21 May
Earnings per share₹18.81₹19.71₹27.95₹29.03₹31.59
Diluted earnings per share₹18.81₹19.71₹27.86₹28.71₹31.14
Dividend per share₹3.50₹4.00₹5.50₹5.80₹6.30
Book value per share₹181.30₹192.42₹216.51₹241.31₹275.20
Dividend payout19.8%19.6%19.7%20.0%20.0%
Shareholder yield−36.0%−4.1%0.4%0.5%0.8%
Market cap at the year end (₹ crore)4584811,0612,1751,553

Ratios

Standalone, years to March.Windlas Biotech PE ratio and valuation

RatioMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 21 May
Revenue growth–10.1%23.0%20.4%19.0%
Operating profit growth–13.9%29.6%20.5%11.2%
Net profit growth–10.6%36.3%4.3%9.5%
Earnings per share growth–4.8%41.8%3.9%8.8%
9.8%10.7%13.6%12.7%12.2%
–0.9 pts2.9 pts−0.9 pts−0.5 pts
From the net margin–0.0 pts1.2 pts−1.8 pts−1.0 pts
From asset turnover–0.6 pts1.0 pts0.0 pts−0.1 pts
From borrowing–0.3 pts0.8 pts0.8 pts0.7 pts
Return on capital employed10.2%11.9%14.4%12.4%12.1%
Cash conversion23.3%143.0%187.3%112.5%157.9%
Interest cover28.860.958.615.115.3
Debt to equity0.020.000.000.050.05
Receivable days8783798092
Inventory days7184576340
Payable days7698121129156
Cash conversion cycle, days82691514−24
Working capital days9072323126
Asset turnover0.951.011.091.101.08
Assets per rupee of net worth1.241.281.351.451.53
Sales per rupee of plant5.145.003.723.894.83
Capital spending to depreciation1.225.732.801.872.20
Plant being built, % of plant in use8.4%13.5%3.4%1.6%30.0%

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
8.0%
Cash from operations against operating profit
100.2%
Measure5 years3 years
Revenue growth, yearly rate–20.8%
Profit growth, yearly rate–15.9%
Return on equity, average11.8%12.8%
Return on capital employed, average12.2%13.0%
Operating margin, average11.9%12.1%
Net margin, average8.2%8.2%
Asset turnover, average1.051.09
Cash conversion cycle, days, average312
Interest cover, average35.729.7
Debt to equity, average0.020.04

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations352282105
Cash from investing−426−258−92
Cash from financing59−27−13
Capital spending24315868
Dividends paid403212
Shares bought back000
Shares issued for cash19640
Borrowings raised30303
Borrowings repaid3100

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––854
Altman Z-scorePublished threshold 1.815.925.136.517.855.47
Beneish M-scorePublished threshold −1.78–−1.59−3.01−2.38−2.03
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–−0.837.159.646.39
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––1.291.471.52
Receivables growth less revenue growthOur threshold 0 percentage points–−4.62−6.362.0117.30
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–19.83−38.5211.76−42.13
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–−0.69−0.241.203.30
Assets under construction, years of additionsOur threshold 2 years of additions–0.570.070.062.50
Effective tax ratePublished threshold 17.16 per cent16.4125.2724.5223.5323.59
Tax charged less tax paid, % of profitOur threshold 10 percentage points−3.088.230.33−2.666.17
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
29 Jun 2026ICRA LimitedFund-based/Non-fund based-Others[ICRA]A+ /[ICRA]A1+Review, Re-affirmStable84.90
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.